Why Aquestive’s Anaphylm is back at FDA after a pouch problem derailed approval
Aquestive Therapeutics has resubmitted its Anaphylm application after responding to FDA concerns over packaging and administration, putting the potential needle-free, orally delivered emergency treatment for anaphylaxis back on a regulatory path toward the U.S. market.
